The potential revenue stream from Rynocil just for kids is extraordinary and I'm happy with discounts for poor kids. US$1.552m for a treatment is way out of reach for the families without insurance.
Hopefully revenue will help development of the next line of exciting drugs - Rynocil for > 18YO, IBD, Crohn's, CLBP (huge market), heart stuff, etc. And that does not take into consideration other uses for the tech. If they can get 50% of these over the line in the next year or 2 MSB could be seen in retrospect as a bargain at $2.
MSB is and alway was a long term investment where patience and big cahoonas should be rewarded.
Ann: Ryoncil Is Now Available For Purchase In The United States, page-100
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.66 |
Change
0.005(0.30%) |
Mkt cap ! $2.114B | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.68 | $1.65 | $5.992M | 3.610M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 31682 | $1.66 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.67 | 102 | 1 |
View Market Depth
| Last trade - 16.10pm 30/06/2025 (20 minute delay) ? |
| MSB (ASX) Chart |